Search

Ming You Phones & Addresses

  • 102 Madison St #5A, New York, NY 10002
  • Long Island City, NY

Professional Records

License Records

Ming Yi You

License #:
FMC15323 - Active
Category:
Food Safety
Issued Date:
May 22, 2007
Expiration Date:
May 22, 2019
Type:
Certified Food Safety Mgr

Ming Hang You

License #:
FMC07856 - Expired
Category:
Food Safety
Issued Date:
Nov 19, 1996
Expiration Date:
Jan 31, 2002
Type:
Certified Food Safety Mgr

Ming Yi You

License #:
FMC15323 - Active
Category:
Food Safety
Issued Date:
May 22, 2007
Expiration Date:
May 22, 2019
Type:
Certified Food Safety Mgr

Business Records

Name / Title
Company / Classification
Phones & Addresses
Ming F. You
Principal
New Hong Kong
Eating Place
1017 154 St, Flushing, NY 11357
Ming G. You
Principal
China Panda
Ret Misc Homefurnishings
351 New Lots Ave, Brooklyn, NY 11207
Ming You
Executive
Kristy Restaurant
Eating Place
796 Courtlandt Ave, Bronx, NY 10451
(718) 402-0698
Ming Jie You
1189 WHOLESALE CORP
Whol Durable Goods
1189 Broadway, New York, NY 10001
50-32 193 St, Fresh Meadows, NY 11365
(212) 686-1988

Publications

Us Patents

Tetrahydroisoquinoline Derivatives Useful As Inhibitors Of Diacylglyceride O-Acyltransferase 2

View page
US Patent:
20170273965, Sep 28, 2017
Filed:
Aug 31, 2015
Appl. No.:
15/508550
Inventors:
- Rahway NJ, US
Rui Liang - East Brunswick NJ, US
Clare London - Chatham NJ, US
Kenneth Marby - San Diego CA, US
James Tata - Westfield NJ, US
Ming You - Monroe NJ, US
Yusheng Xiong - Plainsboro NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/47
A61K 31/16
C07C 13/04
C07D 217/06
Abstract:
The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula (I) are inhibitors of diacylglyceride O-acyltransferase 2 (“DGAT2”) and may be useful in the treatment, prevention and suppression of diseases mediated by DGAT2. The compounds of the present invention may be useful in the treatment of hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions.

Tetrahydroisoquinoline Derivatives Useful As Inhibitors Of Diacylglyceride O-Acyltransferase 2

View page
US Patent:
20170273966, Sep 28, 2017
Filed:
Aug 31, 2015
Appl. No.:
15/508557
Inventors:
- Rahway NJ, US
Clare London - Chatham NJ, US
Zhijian Lu - Plainfield IN, US
James Tata - Westfield NJ, US
Yusheng Xiong - Plainsboro NJ, US
Ming You - Monroe NJ, US
Hyewon Youm - Berkeley Heights NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/47
C07C 13/04
A61K 31/16
C07D 217/06
Abstract:
The present invention relates to a compound represented by formula I:and pharmaceutically acceptable salts thereof. The compounds of formula I are inhibitors of diacylglyceride O-acyltransferase 2 (“DGAT2”) and may be useful in the treatment, prevention and suppression of diseases mediated by DGAT2. The compounds of the present invention may be useful in the treatment of hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cardio renal diseases such as chronic kidney diseases and heart failure and related diseases and conditions.

Isoquinoline Derivatives Useful As Inhibitors Of Diacylglyceride O-Acyltransferase 2

View page
US Patent:
20170275274, Sep 28, 2017
Filed:
Aug 31, 2015
Appl. No.:
15/508562
Inventors:
Jason IMBRIGLIO - Kenilworth NJ, US
Clare LONDON - Chatham NJ, US
Zhijian LU - Plainfield IN, US
James TATA - Kenilworth NJ, US
Yusheng XIONG - Kenilworth NJ, US
Ming YOU - Monroe NJ, US
Hye Won YOUM - Kenilworth NJ, US
- Rahway NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C07D 417/12
C07D 217/02
C07D 401/04
C07D 405/12
C07D 401/14
C07D 413/12
C07D 401/12
Abstract:
The present invention relates to a compound represented by formula I: and pharmaceutically acceptable salts thereof. The compounds of formula I are inhibitors of diacylglyceride O-acyltransferase 2 (“DGAT2”) and may be useful in the treatment, prevention and suppression of diseases mediated by DGAT2. The compounds of the present invention may be useful in the treatment of hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cardio-renal diseases such as chronic kidney diseases and heart failure and related diseases and conditions.
Ming J You from New York, NY, age ~45 Get Report